The Clinical Effect of Sugammadex Sodium (Domestic) for Antagonizing Neuromuscular Blockade After Thoracic Surgery

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age19-75
SponsorThe Fourth Affiliated Hospital of Zhejiang University School of Medicine

About this trial

This study aims to compare the use of sugammadex (domestic) and neostigmine for antagonism after thoracic surgery, and observe the effect of sugammadex (domestic) on neuromuscular blockade antagonism after thoracic surgery, in order to provide a basis for optimizing the use of muscle relaxants and their antagonists during anesthesia.

Eligibility criteria

Qualifiers

Patients who undergo elective lung surgery under general anesthesia and require endotracheal intubation;

Age>18 years old, gender not limited;

American Society of Anesthesiologists ASA Level I-III;

Use rocuronium bromide for neuromuscular blockade;

Disqualifiers

The patient explicitly refused to participate in this trial;

Family history of malignant hyperthermia, patients with allergies to sodium sulbactam, neostigmine ingredients and their excipients, and patients with allergies to drugs used during general anesthesia;

Patients with tracheal malformations or suspected difficult airways, coagulation dysfunction, severe liver and kidney dysfunction, and severe lung disease;

Patients who are not extubated and sent to the ward or ICU after surgery;

Trial design

Treatments tested in this trial

  • SUGAMMADEX SODIUM 100 Mg in 1 mL
  • Neostigmine

Treatment groups

80 Participants
are divided into 2 treatment groups